Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib versus standard second-line chemotherapy for advanced non-small cell lung cancer after first-line treatment failure
ChiCTR1900021201Phase 4Not yet recruiting
- Sponsor
- Affiliated Hospital of Inner Mongolia Medical University
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of anlotinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Affiliated Hospital of Inner Mongolia Medical University. Primary endpoint: Overall survival. Planned start Mar 2019; status: not yet recruiting.
02
Drugs
anlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR1900021201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021201.